Sofokast 400 mg (sofosbuvir) has been a reliable addition to direct-acting antiviral (DAA) medications against chronic hepatitis C virus infection since their inception. Sofokast is indicated for HCV genotypes 1-4. Furthermore, the anti-HCV medicine lowers the risk of liver cancer and enhances patients’ overall quality of life.
Sofosbuvir, unlike its competitors, is known to block the actions of the NS5B protein. This protein is necessary for HCV to proliferate.